Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Collegium Pharmaceutical (COLL)

Collegium closes $980 million syndicated credit facility, repays prior loan

Neutral Impact 3 of 5 financing Written later

Collegium entered a $980 million credit agreement on December 23, 2025, with Truist Bank as administrative agent. The facility includes a $580 million term loan, a $300 million delayed draw term loan, and a $100 million revolving credit facility, and the company used the initial term loan to repay its existing credit agreement in full. The new loans carry interest at SOFR plus 2.75% to 3.75%, based on the company's leverage ratio, and the company says the lower rate is expected to produce meaningful annualized interest savings.

Key points

  • The $980 million facility includes a $580 million term loan, $300 million delayed draw term loan and $100 million revolver, with the last two undrawn at closing.
  • The initial term loan repaid the remaining balance of the existing loan, which the press release cites as approximately $581 million of principal, with the prepayment premium and make-whole amount also paid.
  • Interest is term SOFR plus a spread of 2.75% to 3.75%, based on the First Lien Net Leverage Ratio; the rate at closing was SOFR plus 2.75%.
  • Scheduled quarterly repayments begin March 31, 2026, and the company may repay the loans at any time without premium or penalty; the facility matures in 2030.

The filing

CompanyCollegium Pharmaceutical (COLL)
Form8-K, current report
Filed with the SECDec 30, 2025, 8:05 AM ET
Accession number0001104659-25-125026

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 30, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.